Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s47. https://doi.org/10.25251/skin.6.supp.47